Psychosis Global Market Report 2025

The psychosis market size has grown strongly in recent years. It will grow from $9.88 billion in 2024 to $10.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to the rising cases of mental health conditions, an increasing demand for mental health therapeutics, the widespread adoption of typical antipsychotics, the expanding use of cognitive behavioral therapy, and the prevalence of stress-inducing global and economic conditions.

The psychosis market size is expected to see strong growth in the next few years. It will grow to $13.13 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing prevalence of stress and associated risk factors, the rising mental health burden due to lifestyle changes, expanding government initiatives, the growing adoption of mindfulness-based interventions and therapy programs, and increasing investments in mental health research and innovative treatments. Major trends include the development of novel drug therapies, advancements in diagnostic technologies, the introduction of innovative injectable drugs, the use of biomarkers, and the growing demand for personalized medicines.

The rising incidence of mental health conditions is expected to drive the growth of the psychosis market. Mental health conditions encompass disorders that affect an individual's mood, thinking, behavior, and overall mental well-being. The increase in these conditions is attributed to factors such as heightened stress levels, lifestyle changes, social isolation, economic pressures, and genetic predisposition. Psychosis treatments support patients through early diagnosis, medical intervention, and specialized therapies, leading to greater use of antipsychotic medications and therapeutic options. For example, in 2024, the National Alliance on Mental Illness, a US-based organization, reported that among individuals in the U.S. aged 18-44, psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations annually. As a result, the rising prevalence of mental health conditions is fueling the growth of the psychosis market.

Companies in the psychosis market are focusing on advancing virtual reality (VR) psychological therapy to enhance treatment outcomes through interactive and personalized mental health interventions. VR psychological therapy involves immersing individuals in controlled, computer-generated environments to reduce distress, improve cognitive function, and enhance social skills through guided interventions, offering a safe and effective approach to symptom management. For instance, in April 2022, OxfordVR, a US-based digital therapeutics company, introduced gameChangeVR, a platform designed to guide patients through cognitive behavioral therapy (CBT) in immersive virtual scenarios. The automated VR therapy, delivered over six weekly sessions, demonstrated significant benefits, particularly for individuals facing severe psychological challenges, by reducing paranoia and enhancing overall quality of life. This innovative technology has the potential to expand access to effective mental health care, addressing clinician shortages and providing a scalable solution for millions of patients with severe mental illness.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition aims to strengthen Bristol Myers Squibb’s neuroscience portfolio by incorporating KarXT, a novel antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics is a US-based biopharmaceutical company specializing in the development of psychosis medications.

Major players in the psychosis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Biogen Idec, Dr. Reddy’s Laboratories Ltd., Lundbeck A/S, Gedeon Richter, Alkermes, Supernus Pharmaceuticals, Acadia Pharmaceuticals, Neuron Pharmaceuticals, Mapi Pharma, Astellas Pharma Inc., Newron Pharmaceuticals S.p.A., Anavex Life Sciences, BioXcel Therapeutics.

North America was the largest region in the psychosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in psychosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the psychosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Psychosis is a mental health condition in which individuals lose touch with reality, experiencing hallucinations, delusions, and disorganized thinking. Rather than being a disorder itself, it is a symptom of various mental illnesses. Early detection enhances treatment outcomes, and effective care through medication, therapy, and support can help individuals regain stability.

The primary types of products for psychosis include tablets, capsules, and injections. Tablets are widely used due to their convenience and precise dosing, ensuring consistent drug levels for effective treatment. The condition encompasses various disease types, including schizophrenia, bipolar disorder, unipolar depression, dementia, and others. These products are distributed through both online and offline channels and are utilized by various end-users, such as hospitals, healthcare clinics, specialty clinics, and others.

The psychosis market research report is one of a series of new reports that provides psychosis market statistics, including the psychosis industry global market size, regional shares, competitors with the psychosis market share, detailed psychosis market segments, market trends, and opportunities, and any further data you may need to thrive in the psychosis industry. This psychosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The psychosis market consists of sales of transdermal patches, nasal sprays, intravenous (IV) infusions, long-acting injectable (LAI) implants, and inhalable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.